Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome

Aliment Pharmacol Ther. 1988 Dec;2(6):535-9. doi: 10.1111/j.1365-2036.1988.tb00728.x.


A double-blind crossover trial of the alpha 2 agonist lidamidine hydrochloride in 72 patients with irritable bowel syndrome is reported. Lidamidine was found to have no significant effect on frequency and severity of abdominal pain or abdominal bloating. It did cause a statistically significant reduction in frequency of defaecation (P = 0.005), but this was of a degree unlikely to be of clinical importance. Although alpha 2 agonists inhibit gastrointestinal motility in animals this study suggests that lidamidine hydrochloride does not have a useful therapeutic role in irritable bowel syndrome.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenergic alpha-Agonists / therapeutic use*
  • Adult
  • Colonic Diseases, Functional / drug therapy*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Phenylurea Compounds / therapeutic use*


  • Adrenergic alpha-Agonists
  • Phenylurea Compounds
  • lidamidine